Sanofi also reported that its trial, EDITION II, showed that U300 demonstrated similar blood sugar control with 23% fewer patients experiencing night-time low blood sugar compared with Lantus.
CONCLUDE was a randomised, open-label, treat-to-target, multinational trial comparing the risk of hypoglycaemia with Tresiba vs insulin glargine U300 in 1,609 adults with type 2 diabetes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback